{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RELAPSING+REMITTING+MULTIPLE+SCLEROSIS&page=3",
    "query": {
      "condition": "RELAPSING REMITTING MULTIPLE SCLEROSIS",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 282,
    "total_pages": 29,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RELAPSING+REMITTING+MULTIPLE+SCLEROSIS&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RELAPSING+REMITTING+MULTIPLE+SCLEROSIS&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T22:37:07.563Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00099502",
      "title": "BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)",
          "type": "DRUG"
        },
        {
          "name": "Copaxone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 2244,
      "start_date": "2003-11",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2008-12-19",
      "last_synced_at": "2026-10-13T22:37:07.563Z",
      "location_count": 57,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099502"
    },
    {
      "nct_id": "NCT04031469",
      "title": "A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease",
      "overall_status": "SUSPENDED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gut Microbiome",
        "Gastrointestinal Microbiome",
        "Autism",
        "Autism Spectrum Disorder",
        "Autism Spectrum Disorder High-Functioning",
        "Alzheimer Disease",
        "Alzheimer Dementia (AD)",
        "Alzheimer Dementia",
        "Alzheimer Disease (AD)",
        "Crohn",
        "Crohn Colitis",
        "Crohn Disease (CD)",
        "Crohn Disease Colon",
        "Myalgic Encephalomyelitis",
        "ME/CFS",
        "Myalgic Encephalomyelitis (ME)",
        "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome",
        "Psoriasis",
        "Psoriasis Annularis",
        "Psoriasis Chronic",
        "Chronic Urinary Tract Infection",
        "Ulcerative Colitis (Disorder)",
        "Ulcerative Colitis (UC)",
        "Ulcerative Colitis Acute",
        "Ulcerative Colitis Chronic",
        "Multiple Sclerosis",
        "Multiple Sclerosis (MS) - Relapsing-remitting",
        "Multiple Sclerosis (MS) Primary Progressive",
        "Constipation Chronic Idiopathic",
        "Constipation",
        "Celiac",
        "Celiac Disease",
        "Celiac Sprue",
        "Lyme Arthritis",
        "Lyme Borreliosis, Nervous System",
        "Lyme Disease, Chronic",
        "Cholesterol",
        "Cholesterol Level, High",
        "Cancer",
        "Colon Cancer",
        "Amyotrophic Lateral Sclerosis (ALS)",
        "Amyotrophic Lateral Sclerosis",
        "Rheumatoid Arthritis (RA)",
        "Rheumatoid Arthritis - Rheumatism",
        "Chronic Fatigue Syndrome (CFS)",
        "PARKINSON DISEASE (Disorder)",
        "Parkinson Disease",
        "Parkinson Disease (PD)",
        "Depression",
        "Major Depressive Disorder (MDD)",
        "Depression Disorder",
        "Depression in Adults",
        "Anxiety",
        "Anxiety Disorder Generalized",
        "Obsessive Compulsive Disorder (OCD)",
        "Obsessive Compulsive Disorder OCD",
        "Obsessive - Compulsive Disorder",
        "Bipolar",
        "Bipolar 1 Disorder",
        "Bipolar Disorder (BD)",
        "Bipolar Disorder I and II",
        "Bipolar and Related Disorders",
        "Migraine",
        "Migraine Disorder",
        "Diabetes (DM)",
        "Diabetes",
        "Lupus",
        "Lupus Erythematosus",
        "Epidermolysis Bullosa (EB)",
        "Mesothelioma",
        "Mesothelioma Malignant",
        "IBS (Irritable Bowel Syndrome)",
        "Irritable Bowel",
        "IBS - Irritable Bowel Syndrome",
        "Irritable Bowel Syndrome (IBS)",
        "Eczema",
        "Eczema Atopic Dermatitis",
        "Acne",
        "Myasthaenia Gravis",
        "Gout"
      ],
      "interventions": [
        {
          "name": "There is no intervention in this study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "ProgenaBiome",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2019-07-11",
      "completion_date": "2030-12-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-13T22:37:07.563Z",
      "location_count": 1,
      "location_summary": "Ventura, California",
      "locations": [
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04031469"
    },
    {
      "nct_id": "NCT01466114",
      "title": "Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsing-remitting Multiple Sclerosis",
        "Secondary-progressive Multiple Sclerosis",
        "Primary-progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "estriol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Norethindrone",
          "type": "DRUG"
        },
        {
          "name": "Progestin Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 64,
      "start_date": "2011-10",
      "completion_date": "2022-04",
      "has_results": false,
      "last_update_posted_date": "2019-11-06",
      "last_synced_at": "2026-10-13T22:37:07.563Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Albuquerque, New Mexico + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01466114"
    },
    {
      "nct_id": "NCT06800404",
      "title": "\"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis\"",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis (RRMS)",
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Autologous HB-adMSCs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hope Biosciences Research Foundation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2025-05-02",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-20",
      "last_synced_at": "2026-10-13T22:37:07.563Z",
      "location_count": 1,
      "location_summary": "Sugar Land, Texas",
      "locations": [
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06800404"
    },
    {
      "nct_id": "NCT02398461",
      "title": "An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis, Acute Relapsing"
      ],
      "interventions": [
        {
          "name": "rHIgM22",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acorda Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 27,
      "start_date": "2015-04",
      "completion_date": "2017-09-21",
      "has_results": false,
      "last_update_posted_date": "2018-08-22",
      "last_synced_at": "2026-10-13T22:37:07.563Z",
      "location_count": 12,
      "location_summary": "Long Beach, California • Sacramento, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02398461"
    },
    {
      "nct_id": "NCT02255656",
      "title": "Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "alemtuzumab GZ402673",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1062,
      "start_date": "2015-01-07",
      "completion_date": "2020-07-15",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-10-13T22:37:07.563Z",
      "location_count": 52,
      "location_summary": "Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02255656"
    },
    {
      "nct_id": "NCT00235989",
      "title": "Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Interferon beta 1b (Betaseron, BAY86-5046)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 63,
      "start_date": "2003-06",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2014-05-08",
      "last_synced_at": "2026-10-13T22:37:07.563Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00235989"
    },
    {
      "nct_id": "NCT05359653",
      "title": "Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis (MS)",
        "Multiple Sclerosis, Relapsing-Remitting",
        "Multiple Sclerosis, Primary Progressive",
        "Multiple Sclerosis, Chronic Progressive",
        "Multiple Sclerosis Relapse",
        "Multiple Sclerosis Brain Lesion",
        "Multiple Sclerosis Benign"
      ],
      "interventions": [
        {
          "name": "Clemastine Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 74,
      "start_date": "2023-08-01",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-13T22:37:07.563Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05359653"
    },
    {
      "nct_id": "NCT06737419",
      "title": "Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2021-06-09",
      "completion_date": "2024-02-05",
      "has_results": false,
      "last_update_posted_date": "2024-12-17",
      "last_synced_at": "2026-10-13T22:37:07.563Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06737419"
    },
    {
      "nct_id": "NCT00229502",
      "title": "Cognitive Effects of Immunomodulatory Drugs in MS",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Sharon Lynch, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 96,
      "start_date": "2005-09",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2012-03-23",
      "last_synced_at": "2026-10-13T22:37:07.563Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00229502"
    }
  ]
}